Comparative Pharmacology
Head-to-head clinical analysis: MELPHALAN HYDROCHLORIDE versus NEOSAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MELPHALAN HYDROCHLORIDE versus NEOSAR.
MELPHALAN HYDROCHLORIDE vs NEOSAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Melphalan is a bifunctional alkylating agent that forms cross-links between DNA strands, inhibiting DNA replication and transcription. It is cell cycle phase-nonspecific.
Alkylating agent that inhibits DNA replication and transcription by cross-linking DNA strands, leading to cell cycle arrest and apoptosis.
16 mg/m² intravenously over 15-20 minutes every 2 weeks for 4 doses, then every 4 weeks
Cyclophosphamide 500-1500 mg/m² IV every 2-4 weeks; oral 50-200 mg daily.
None Documented
None Documented
1.5-2.5 h (terminal) in normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life: 3-5 hours; prolonged in hepatic impairment (up to 12 hours).
Renal: 10-30% unchanged; fecal: 20-30% as metabolites; biliary: minor.
Renal: 30-60% unchanged; biliary/fecal: 10-20% as metabolites.
Category D/X
Category C
Alkylating Agent
Alkylating Agent